Global Ipilimumab Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 2.03 Million |
 Market Size (Forecast Year) |
USD 4.34 Million |
 CAGR |
% |
| Major Markets Players |
全球 Ipilimumab 市场，按类型（PD-L1 拮抗剂、CTLA4 拮抗剂、免疫检查点抑制剂、其他）、应用（癌症、黑色素瘤、其他）、作用机制（抗体依赖性细胞毒性、细胞毒性 T 淋巴细胞抗原 4 抑制剂、T 淋巴细胞兴奋剂）、剂量（液体、注射剂、其他）、给药途径（静脉注射、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他）划分 – 行业趋势和预测到 2029 年。
市场分析和规模
近年来，由于癌症发病率不断上升，预计预测期内伊匹单抗市场将快速增长。根据国际癌症研究机构 (IARC) 的数据，到 2040 年，全球癌症负担预计将增加到 2750 万新病例，死亡人数将达到 1630 万。黑色素瘤是一种皮肤癌，因过度暴露于紫外线 (UV) 而导致皮肤起泡晒伤。伊匹单抗是一种针对抗细胞毒性 T 淋巴细胞抗原 (CTLA)-4 的单克隆抗体。它在美国被批准用于恶性黑色素瘤患者的一线或二线治疗。
Data Bridge Market Research 分析，2021 年 ipilimumab? 市场价值为 202.6 万美元，预计到 2029 年将达到 434 万美元，在 2022 年至 2029 年的预测期内复合年增长率为 10.0%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
市场定义
伊匹单抗是一种用于治疗癌症的免疫疗法药物。免疫疗法是全身性的，这意味着疗法通过血液流向身体的各个部位。从原发部位扩散到身体各个部位的癌症可以用全身癌症疗法治疗。伊匹单抗的作用是抑制一种阻止免疫系统正确攻击癌细胞的蛋白质。它有助于免疫系统检测和消除癌细胞。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（PD-L1 拮抗剂、CTLA4 拮抗剂、免疫检查点抑制剂、其他）、应用（癌症、黑色素瘤、其他）、作用机制（抗体依赖性细胞毒性、细胞毒性 T 淋巴细胞抗原 4 抑制剂、T 淋巴细胞刺激剂）、剂量（液体、注射剂、其他）、给药途径（静脉注射、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
AstraZeneca (UK), Sanofi (France), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (US), Incyte (US), Baxter (US) |
|
Market Opportunities |
|
Ipilimumab? Market Dynamics
Drivers
- Increasing prevalence of cancer
The rising prevalence of cancer is a primary driver of the ipilimumab? market's growth.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of ipilimumab? market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the ipilimumab? market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of ipilimumab? market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the ipilimumab? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the ipilimumab? market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the ipilimumab? market. Additionally, strict guidelines as well as regulations and side effects of ipilimumab? such as headache, nausea, anemia, fatigue and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This ipilimumab? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ipilimumab? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Ipilimumab? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Ipilimumab? Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The ipilimumab market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the ipilimumab market's revenue trajectory.
Recent Development
- In November 2021, Bristol-Myers Squibb Company had received the U.S. Food and Drug Administration approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer. Patients with squamous or non-squamous illness, independent of PD-L1 expression, are eligible for the treatment. 1 The FDA's Real-Time Oncology Examine (RTOR) pilot programme was used to review this application, which aims to ensure that safe and effective medicines are offered to patients as soon as feasible.
Global Ipilimumab? Market Scope
The ipilimumab? market is segmented on the basis of type, application, mechanism of action, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- PD – L1 Antagonists
- CTLA4 Antagonists
- Immunocheckpoint Inhibitors
- Other
On the basis of type, the global hepatic drugs market is segmented into PD – L1 antagonists, CTLA4 antagonists, immunocheckpoint inhibitors, and other.
Application
- Cancer
- Melanoma
- Others
On the basis of application, the global hepatic drugs market is segmented into cancer, melanoma and others.
Mechanism of Action
- Antibody-Dependent Cell Cytotoxicity
- Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
- T Lymphocyte Stimulants
On the basis of mechanism of action, the global hepatic drugs market is segmented into antibody-dependent cell cytotoxicity, cytotoxic T-lymphocyte antigen 4 inhibitors, and T lymphocyte stimulants.
Dosage
- Liquids
- Injectables
- Others
On the basis of dosage, the ipilimumab? market is segmented into liquids, injectables and others.
Route of Administration
- Intravenous
- Others
The route of administration segment for the ipilimumab? market is segmented into intravenous and others.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the ipilimumab? market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the ipilimumab? market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Ipilimumab? Market Regional Analysis/Insights
The Ipilimumab? market is analysed and market size insights and trends are provided by country, type, application, mechanism of action, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Ipilimumab? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the ipilimumab? market because of the growing prevalence rate if cancer in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.
由于医疗保健支出的增加和医疗保健基础设施的改善，预计亚太地区在 2022 年至 2029 年的预测期内将实现增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和 Ipilimumab市场份额分析
Ipilimumab? 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对 ipilimumab? 市场的关注有关。
在 ipilimumab 市场运营的一些主要参与者是：
- 阿斯利康（英国）
- 赛诺菲（法国）
- 百时美施贵宝公司 (美国)
- 吉利德科学公司（美国）
- 默克集团（德国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- 诺华公司（瑞士）
- 默克公司（美国）
- Incyte (美国)
- 百特（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
